In the claims:

Please amend claims as follows (for the convenience of the Examiner, all claims, whether or not amended, are presented below):

8. **(Amended)** An active immunoglobulin fusion protein (Ig-fusion protein) obtained by culturing a mammalian host cell transformed with DNA encoding the fusion in a culture system having a low temperature of about 27° C to about 35 ° C.

A3

9. **(Amended)** The Ig-fusion protein of claim 8 comprising a member of the TNF family.

10. **(Amended)** The Ig-fusion protein of claim 9 comprising LT-B receptor.

11. **(Amended)** The Ig-fusion protein of claim 9 comprising herpes virus entry mediator (HVEM).

16. **(Amended)** A pharmaceutical preparation obtained by

(a) culturing a host transformed with DNA encoding an Ig-fusion protein in a culture system having a low temperature of about 27° C to about 32 ° C, thereby expressing active Ig-fusion proteins;

(b) recovering active Ig-fusion proteins from said culture system; and

A4

(c) combining the active Ig-fusion proteins of step (b) with a pharmaceutically acceptable carrier.

17. **(Amended)** The pharmaceutical preparation of claim 16 wherein the Ig- fusion protein comprises a member of the TNF family.

18. **(Amended)** The pharmaceutical preparation of claim 17 wherein the Ig- fusion protein comprises a lymphotoxin-B receptor.

A4

19. **(Amended)** The pharmaceutical preparation of claim 17 wherein the Ig-fusion protein comprises HVEM.

26. **(Amended)** An active Ig-fusion protein obtained by culturing yeast transformed with DNA encoding the fusion in a culture system having a low temperature of about 10° C to about 25 ° C.

A5

27. **(Amended)** The Ig-fusion protein of claim 26 comprising a member of the TNF family.

28. **(Amended)** The Ig-fusion protein of claim 27 comprising LT-B receptor, or a fragment thereof.

29. **(Amended)** The Ig-fusion protein of claim 26 comprising HVEM, or a fragment thereof.